Snehal Patel, the CEO and CFO of $GLSI ($GLSI), bought 2,400 shares of the company on 12-31-2024. This trade was reported by Quiver Quantitative using data from a ...
Greenwich LifeSciences is continuing to develop a HER2 vaccine for HER2-positive breast cancer. Recently announced data give a preliminary glimmer that the vaccine is doing something in patients, but ...
Greenwich Lifesciences shares are trading higher by 30.6% Wednesday afternoon. The company provided an update on the Phase III clinical trial, Flamingo-01. Discover the top trade setups and strategies ...
Greenwich LifeSciences, Inc. (NASDAQ: GLSI) shares are trading higher Monday after the company announced it extended its lock-up period to Sept. 30, 2026. What To Know: Greenwich LifeSciences said its ...
Asianet Newsable on MSN
Why is GLSI stock rising today?
Greenwich LifeSciences said its Phase III breast cancer immunotherapy trial, involving 250 patients, showed a recurrence rate ...
The company is running a Phase III study known as FLAMINGO-01, which is testing GLSI-100. The approval follows the submission of manufacturing and stability data tied to multiple production runs. More ...
Greenwich LifeSciences (NASDAQ:GLSI) just reported results for the fourth quarter of 2023. Greenwich LifeSciences reported earnings per share of -21 cents. This was below the analyst estimate for EPS ...
Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Greenwich LifeSciences, Inc. (NASDAQ: GLSI) concerning the Company and its directors’ and officers’ possible violations of state laws ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results